Latest Breaking News On - Kyle gano - Page 4 : comparemela.com

Another UK Biotech Snapped Up As Neurocrine Buys Diurnal

Neurocrine, with latest deal, gets a foothold in Europe

BioPharma

Brain-focused Neurocrine buys a biotech to broaden its scope in hormone disorders

Neurocrine Biosciences is acquiring Diurnal Group, a U.K-based biotech that has commercialized two endocrine disorder drugs. Neurocrine’s top-selling product is a blockbuster drug for an involuntary muscle movement disorder.

Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript

NBIX earnings call for the period ending June 30, 2022.

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2022 Results - Earnings Call Transcript

Neurocrine Biosciences, Inc. (NASDAQ:NASDAQ:NBIX) Q1 2022 Earnings Conference Call May 04, 2022, 08:00 ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO & Director Matthew.